🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Amy D. Rose

National Laboratory of the Rockies

ORCID: 0000-0001-7226-9357

Also affiliated with Los Angeles Clinical Trials, University of California, Davis

Social SciencesMedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results”.

605 Neoadjuvant vidutolimod (vidu) and nivolumab (nivo) results in MPR and immune activation in high-risk resectable melanoma (MEL): final phase II clinical trial results

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.0605

N/A

0.272DataRank · unranked

4 citations

Joë-Marc Chauvin, Robert Morrison, Yulong Bai, Jie Sun, Hong Wang +22 more

Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

medRxiv(2025)10.1101/2025.11.04.25339499

N/A

0.165DataRank · unranked

2 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +16 more

1340 Lead-in therapy targeting PD1 and/or LAG3 distinguishes differential impacts upon the immune response in first-line treatment of metastatic melanoma

(2025)10.1136/jitc-2025-sitc2025.1340

N/A

0DataRank · unranked

0 citations

Anthony R. Cillo, Shuaichao Wang, Arivarasan Karunamurthy, Ryan Massa, Anjali Rohatgi +15 more